Prof. Dingzhi Huang 黄鼎智
Chief Physician, Professor
Department of Lung Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy (adjuvant, neoadjuvant, salvage), targeted therapy, and immunotherapy for lung cancer and other solid tumors. Uses a multidisciplinary team (MDT) approach.
Dr. Huang holds a PhD and serves as Chief Physician and Associate Professor. Research focuses on tumor microenvironment regulation and cancer stem cells. Recognized multiple times as an Excellent Attending Physician and Top Ten Attending Physician for standardized, individualized clinical care.
Professional roles
- Deputy Chair, Youth Committee of Targeted Therapy Professional Committee, China Anti-Cancer Association
- Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Member, Tumor Precision Treatment Professional Committee, China Anti-Cancer Association
- Deputy Chair, Liquid Biopsy Professional Committee, China Lung Cancer Prevention and Treatment Alliance
Name order: in Chinese the family name comes first (Huang Dingzhi). Papers usually list the name as Dingzhi Huang or Huang D.
Selected publications
103 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Biol Med, 2026 (senior author): Efbemalenograstim alfa as prophylaxis for chemotherapy-induced neutropenia in patients with non-small-cell lung cancer: a randomized, multicenter, phase II trial. PubMed 42773790
- Nat Commun, 2026 (senior author): XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer. PubMed 42768009
- Mol Cancer, 2026 (senior author): HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling. PubMed 41501879
- Thorac Cancer, 2025 (senior author): NFAT5 Regulates IL8 to Promote Cell Growth and Migration in Non-Small Cell Lung Cancer. PubMed 41188193
- Cancer Biol Med, 2025 (senior author): Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway. PubMed 41131865
- Cancer Biol Med, 2025 (senior author): XPO1 as a key regulator in small cell lung cancer: mechanisms, biomarkers, and therapeutic implications. PubMed 40579892
- Adv Sci (Weinh), 2025 (senior author): Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer. PubMed 39887933
- Thorac Cancer, 2025 (senior author): ACT001 Suppresses the Malignant Progression of Small-Cell Lung Cancer by Inhibiting Lactate Production and Promoting Anti-Tumor Immunity. PubMed 40016971
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion